还可以
MAT2A-IN-5, a potent inhibitor of MAT2A, effectively targets the abnormally elevated expression of MAT2A found in various tumor types such as gastric, colon, liver, and pancreatic cancers. By reducing the proliferative activity of MTAP-deficient cancer cells, MAT2A-IN-5 exhibits potential in cancer research applications [1].
还可以MAT2A-IN-5, a potent inhibitor of MAT2A, effectively targets the abnormally elevated expression of MAT2A found in various tumor types such as gastric, colon, liver, and pancreatic cancers. By reducing the proliferative activity of MTAP-deficient cancer cells, MAT2A-IN-5 exhibits potential in cancer research applications [1].
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 6-8周 | |
| 50 mg | ¥ 13,800 | 6-8周 | |
| 100 mg | ¥ 17,500 | 6-8周 |
| 产品描述 | MAT2A-IN-5, a potent inhibitor of MAT2A, effectively targets the abnormally elevated expression of MAT2A found in various tumor types such as gastric, colon, liver, and pancreatic cancers. By reducing the proliferative activity of MTAP-deficient cancer cells, MAT2A-IN-5 exhibits potential in cancer research applications [1]. |
| 分子量 | 352.74 |
| 分子式 | C17H12ClF3N2O |
| CAS No. | 2756458-55-4 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， 一共给药动物 10 只 ，您使用的配方为 5% 
DMSO+ 30%PEG300+ 5%Tween 80 + 60%Saline/PBS/ddH2O， 那么您的工作液浓度为 2 mg/mL 。 母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween 80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清 以上为“体内实验配液计算器”的使用方法举例，并不是具体某个化合物的推荐配制方式，请根据您的实验动物和给药方式选择适当的溶解方案。
嗨！有任何问题？点我咨询
评论内容